Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of C225 (Erbitux or cetuximab) in combination with cisplatin and definitive radiation in unresectable stage IV squamous cell carcinoma of the head and neck

Next Previous
X
Search
Trial Profile

Phase II study of C225 (Erbitux or cetuximab) in combination with cisplatin and definitive radiation in unresectable stage IV squamous cell carcinoma of the head and neck

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin (Primary)
  • Indications Carcinoma; Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 Dec 2018 Status changed from active, no longer recruiting to completed.
    • 24 Mar 2011 Planned end date (Jul 2016) added as reported by ClinicalTrials.gov.
    • 17 May 2008 Preliminary results will be presented at ASCO 2008 according to a ImClone Systems media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top